Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

19 Jan 2024

Short strands of toxic RNAs contribute to brain cell death and DNA damage in Alzheimer's

Alzheimer's disease, which is expected to have affected about 6.7 million patients in the U.S. in 2023, results in a substantial loss of brain cells.

18 Jan 2024

Conscience's open science competition yields hits for new Parkinson's drugs

As part of its pioneering approach to drug discovery, the Canadian nonprofit Conscience announced today that its first open science competition has resulted in the identification of seven promising molecules, or "hits," that show potential for new, more effective drugs for familial Parkinson's disease.

16 Jan 2024

Pioneering Genomic Progress: An Interview with Rami Mehio, Illumina's Software and Informatics Expert

In this interview, Rami Mehio, head of software and informatics at Illumina, shares his experiences and contributions to major genomic projects like the UK Biobank's whole genome sequencing. He discusses the challenges and innovations in genomic data analysis, highlighting Illumina's role in advancing genetic research and precision medicine.

From Illumina, Inc. 15 Jan 2024

New analysis of cancer cells identifies 370 targets for smarter, personalized treatments

A new, systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types, including breast, lung and ovarian cancers.

13 Jan 2024

3D nanomatrix vascular sheet model for high-throughput atherosclerosis drug testing

A groundbreaking 3D, three-layer nanomatrix vascular sheet that possesses multiple features of atherosclerosis has been applied for developing a high-throughput functional assay of drug candidates to treat this disease, University of Alabama at Birmingham researchers report in the journal Biomaterials.

12 Jan 2024

When mass spectrometry redefines the pharma industry

In this new episode of omg OMx, Kate Stumpo speaks to Bruker's Mike Greig about the incredible potential of mass spectrometry in pharma.

From Bruker Life Sciences Mass Spectrometry 12 Jan 2024

New molecule targets key protein in autoimmune diseases

Scientists from Scripps Research have developed a small molecule that blocks the activity of a protein linked to autoimmune diseases, including systemic lupus erythematosus (SLE) and Crohn's disease.

11 Jan 2024

New developments at Evosep to make clinical proteomics 100x more robust and 10x faster

J.P. Morgan Healthcare Conference – (January 8th, 2024) Evosep, a leading provider of sample preparation solutions for mass spectrometry-based proteomics, today announced a co-marketing agreement with Thermo Fisher Scientific, a world leader in serving science.

From Thermo Fisher Scientific Inc. 10 Jan 2024

SickKids scientists untangle cellular waste buildup in Zellweger Spectrum Disorder

For the first time, a research team at The Hospital for Sick Children (SickKids) has uncovered a way to potentially reduce the amount of toxic cellular waste accumulating in patients with Zellweger Spectrum Disorder (ZSD).

9 Jan 2024

Scripps scientists debunk long-held theory about alcohol and the brain

Ethanol-;the compound found in alcoholic beverages-;interferes with the normal functioning of a long list of biological molecules, but how each of these interactions contributes to the behavioral effects of alcohol is not fully understood.

8 Jan 2024

New test detects Parkinson's disease before symptoms appear

In the development of Parkinson's disease (PD), the changes that will lead to neurodegeneration take place in the brain long before patients show any symptoms.

8 Jan 2024

Scripps Research commemorates 100 years of innovation in science and medicine

Scripps Research, a nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation, will celebrate its 100-year history throughout 2024.

5 Jan 2024

Researchers develop peptide to target "chaotic" MYC protein in 75% of cancers

Meet MYC, the shapeless protein responsible for making the majority of human cancer cases worse.

4 Jan 2024

New synthetic antibiotic found to be more effective than established drugs against 'superbugs'

A new synthetic antibiotic developed by University of Liverpool researchers is shown to be more effective than established drugs against 'superbugs' such as MRSA, a new study shows.

3 Jan 2024

"Genetic priority score" promises to revolutionize drug development

Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel "genetic priority score" (GPS) that will integrate various types of human genetic data into a single easy-to-interpret score.

3 Jan 2024

AI Integration in the Fight Against Age-Related Macular Degeneration

In this interview, Wen Hwa Lee, CEO, and Chief Scientist at Action Against Age-Related Macular Degeneration (AAAMD), offers an enlightening perspective on merging AI with ophthalmology to forge new paths in healthcare and drug discovery.

From ELRIG (UK) Ltd. 3 Jan 2024

Scripps scientists develop powerful method to find drug targets in live cells

Identifying new ways to target proteins involved in human diseases is a priority for many researchers around the world.

2 Jan 2024

Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

28 Dec 2023

Degron Therapeutics announced as winner of AFCR's 2023 BRACE Award Venture Competition

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition.

27 Dec 2023